Skip to main content

Table 1 The relationship between S100A2 mRNA expression and clinical characteristics in endometrial carcinoma

From: High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma

Characteristic Low expression of S100A2 High expression of S100A2 P value
n 276 276  
Clinical stage, n (%) 0.028
  Stage I 186 (33.7%) 156 (28.3%)  
  Stage II 22 (4%) 29 (5.3%)  
  Stage III 52 (9.4%) 78 (14.1%)  
  Stage IV 16 (2.9%) 13 (2.4%)  
Primary therapy outcome, n (%) 0.864
  PD 11 (2.3%) 9 (1.9%)  
  SD 2 (0.4%) 4 (0.8%)  
  PR 6 (1.2%) 6 (1.2%)  
  CR 218 (45.4%) 224 (46.7%)  
Race, n (%) 0.549
  Asian 10 (2%) 10 (2%)  
  Black or African
  American
60 (11.8%) 48 (9.5%)  
  White 188 (37.1%) 191 (37.7%)  
Age, n (%) 0.766
  <=60 101 (18.4%) 105 (19.1%)  
  >60 174 (31.7%) 169 (30.8%)  
Weight, n (%) 0.727
  <=80 124 (23.5%) 119 (22.5%)  
  >80 140 (26.5%) 145 (27.5%)  
BMI, n (%) 0.219
  <=30 114 (22%) 98 (18.9%)  
  >30 147 (28.3%) 160 (30.8%)  
Histological type, n (%) 0.014
  Endometrioid 220 (39.9%) 190 (34.4%)  
  Mixed 9 (1.6%) 15 (2.7%)  
  Serous 47 (8.5%) 71 (12.9%)  
Residual tumor, n (%) 0.962
  R0 198 (47.9%) 177 (42.9%)  
  R1 12 (2.9%) 10 (2.4%)  
  R2 8 (1.9%) 8 (1.9%)  
Histologic grade, n (%) 0.658
  G1 51 (9.4%) 47 (8.7%)  
  G2 63 (11.6%) 57 (10.5%)  
  G3 156 (28.8%) 167 (30.9%)  
Tumor invasion(%), n (%) 0.402
  <50 134 (28.3%) 125 (26.4%)  
  >=50 102 (21.5%) 113 (23.8%)  
Menopause status, n (%) 0.038
  Pre 23 (4.5%) 12 (2.4%)  
  Peri 5 (1%) 12 (2.4%)  
  Post 221 (43.7%) 233 (46%)  
Hormones therapy, n (%) 0.578
  No 143 (41.6%) 154 (44.8%)  
  Yes 20 (5.8%) 27 (7.8%)  
Radiation therapy, n (%) 0.177
  No 148 (28.1%) 131 (24.9%)  
  Yes 116 (22%) 132 (25%)  
Diabetes, n (%) 0.158
  No 155 (34.4%) 173 (38.4%)  
  Yes 68 (15.1%) 55 (12.2%)